vs
Side-by-side financial comparison of Bio-Techne (TECH) and Ultra Clean Holdings, Inc. (UCTT). Click either name above to swap in a different company.
Ultra Clean Holdings, Inc. is the larger business by last-quarter revenue ($533.7M vs $295.9M, roughly 1.8× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -2.8%, a 15.7% gap on every dollar of revenue. On growth, Ultra Clean Holdings, Inc. posted the faster year-over-year revenue change (2.9% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 1.7%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Ultra Clean Holdings, Inc. is a leading global supplier of critical subsystems, ultra-high purity cleaning services, and precision process components for the semiconductor, advanced display, and life sciences sectors. It operates across North America, Asia, and Europe, serving top semiconductor fabs and high-tech equipment manufacturers to support advanced microelectronics production.
TECH vs UCTT — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $533.7M |
| Net Profit | $38.0M | $-15.0M |
| Gross Margin | 64.6% | 12.2% |
| Operating Margin | 18.4% | 2.1% |
| Net Margin | 12.8% | -2.8% |
| Revenue YoY | -6.4% | 2.9% |
| Net Profit YoY | 68.3% | -500.0% |
| EPS (diluted) | $0.24 | $-0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $533.7M | ||
| Q4 25 | $295.9M | $506.6M | ||
| Q3 25 | — | $510.0M | ||
| Q2 25 | $317.0M | $518.8M | ||
| Q1 25 | $316.2M | $518.6M | ||
| Q4 24 | $297.0M | $563.4M | ||
| Q3 24 | $289.5M | $540.4M | ||
| Q2 24 | $306.1M | $516.1M |
| Q1 26 | — | $-15.0M | ||
| Q4 25 | $38.0M | $-3.3M | ||
| Q3 25 | — | $-10.9M | ||
| Q2 25 | $-17.7M | $-162.0M | ||
| Q1 25 | $22.6M | $-5.0M | ||
| Q4 24 | $34.9M | $16.3M | ||
| Q3 24 | $33.6M | $-2.3M | ||
| Q2 24 | $40.6M | $19.1M |
| Q1 26 | — | 12.2% | ||
| Q4 25 | 64.6% | 15.2% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | 62.7% | 15.3% | ||
| Q1 25 | 67.9% | 16.2% | ||
| Q4 24 | 65.3% | 16.3% | ||
| Q3 24 | 63.2% | 17.3% | ||
| Q2 24 | 66.4% | 17.1% |
| Q1 26 | — | 2.1% | ||
| Q4 25 | 18.4% | 2.2% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | -7.5% | -27.3% | ||
| Q1 25 | 12.2% | 2.5% | ||
| Q4 24 | 16.0% | 4.6% | ||
| Q3 24 | 13.8% | 4.7% | ||
| Q2 24 | 15.0% | 4.4% |
| Q1 26 | — | -2.8% | ||
| Q4 25 | 12.8% | -0.7% | ||
| Q3 25 | — | -2.1% | ||
| Q2 25 | -5.6% | -31.2% | ||
| Q1 25 | 7.1% | -1.0% | ||
| Q4 24 | 11.7% | 2.9% | ||
| Q3 24 | 11.6% | -0.4% | ||
| Q2 24 | 13.3% | 3.7% |
| Q1 26 | — | $-0.40 | ||
| Q4 25 | $0.24 | $-0.07 | ||
| Q3 25 | — | $-0.24 | ||
| Q2 25 | $-0.11 | $-3.58 | ||
| Q1 25 | $0.14 | $-0.11 | ||
| Q4 24 | $0.22 | $0.36 | ||
| Q3 24 | $0.21 | $-0.05 | ||
| Q2 24 | $0.26 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $323.5M |
| Total DebtLower is stronger | $260.0M | $601.9M |
| Stockholders' EquityBook value | $2.0B | $702.1M |
| Total Assets | $2.5B | $1.9B |
| Debt / EquityLower = less leverage | 0.13× | 0.86× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $323.5M | ||
| Q4 25 | $172.9M | $311.8M | ||
| Q3 25 | — | $314.1M | ||
| Q2 25 | $162.2M | $327.4M | ||
| Q1 25 | $140.7M | $317.6M | ||
| Q4 24 | $177.5M | $313.9M | ||
| Q3 24 | $187.5M | $318.2M | ||
| Q2 24 | $152.9M | $319.5M |
| Q1 26 | — | $601.9M | ||
| Q4 25 | $260.0M | $481.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | $346.0M | — | ||
| Q1 25 | $330.0M | — | ||
| Q4 24 | $300.0M | $499.7M | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $319.0M | — |
| Q1 26 | — | $702.1M | ||
| Q4 25 | $2.0B | $711.0M | ||
| Q3 25 | — | $709.9M | ||
| Q2 25 | $1.9B | $719.4M | ||
| Q1 25 | $2.0B | $872.0M | ||
| Q4 24 | $2.1B | $873.6M | ||
| Q3 24 | $2.1B | $857.9M | ||
| Q2 24 | $2.1B | $852.3M |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $2.5B | $1.7B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | $2.6B | $1.7B | ||
| Q1 25 | $2.6B | $1.9B | ||
| Q4 24 | $2.7B | $1.9B | ||
| Q3 24 | $2.7B | $1.9B | ||
| Q2 24 | $2.7B | $1.9B |
| Q1 26 | — | 0.86× | ||
| Q4 25 | 0.13× | 0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.14× | 0.57× | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
UCTT
| Products | $465.7M | 87% |
| Services | $68.0M | 13% |
